An Analysis of Extended Survival in Patients With Amyotrophic Lateral Sclerosis Treated With Riluzole

BACKGROUND In an attempt to better understand and define the progression of amyotrophic lateral sclerosis (ALS), we developed a classification of 5 discrete health states that reflect patients' activities of daily living. These health states were used to determine whether patients with ALS who...

Full description

Saved in:
Bibliographic Details
Published inArchives of neurology (Chicago) Vol. 55; no. 4; pp. 526 - 528
Main Authors Riviere, Marc, Meininger, Vincent, Zeisser, Phillipe, Munsat, Theodore
Format Journal Article
LanguageEnglish
Published Chicago, IL American Medical Association 01.04.1998
Subjects
Amyotrophic Lateral Sclerosis - drug therapy
Amyotrophic Lateral Sclerosis - mortality
Biological and medical sciences
Excitatory Amino Acid Antagonists - therapeutic use
Humans
Medical sciences
Miscellaneous
Neuropharmacology
Pharmacology. Drug treatments
Proportional Hazards Models
Riluzole - therapeutic use
Risk Factors
Survival Rate
Treatment Outcome
Human
Nervous system diseases
Psychotropic
Health
Daily living
Benzothiazole
Psychometrics
Activity
Amyotrophic lateral sclerosis
Riluzole
Chemotherapy
Treatment
Central nervous system disease
Classification
Evolution
Degenerative disease
Spinal cord disease
Comparative study
Online AccessGet full text

Cover

More Information
Summary:BACKGROUND In an attempt to better understand and define the progression of amyotrophic lateral sclerosis (ALS), we developed a classification of 5 discrete health states that reflect patients' activities of daily living. These health states were used to determine whether patients with ALS who are treated with riluzole differed from those treated with placebo. SETTING Clinics for patients with ALS. DESIGN Placebo-controlled trial of riluzole treatment in 959 patients with ALS. INTERVENTIONS Treatment with riluzole or placebo. MAIN DEPENDENT MEASURES A Cox model was used to assess whether, from the initial randomization to the end of an 18-month follow-up, there was a difference in the times of transition into subsequent health states between patients treated with riluzole and those treated with placebo. RESULTS Our analysis showed a significant difference in the time to transit between the riluzole and the placebo groups in less severely affected cases, ie, state 2 and state A (the milder states) of ALS. CONCLUSION Patients receiving riluzole remained in the milder health states longer (P<.05).Arch Neurol. 1998;55:526-528-->
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
ISSN:0003-9942
2168-6149
1538-3687
2168-6157
DOI:10.1001/archneur.55.4.526